About this trial
Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University Hospital, with a combination of carbon ions and photons. So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); patients are followed up for further 5 years after the start of therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70% after 5 years (primary objective criterion of this study). In order to reject the null hypothesis with a power of 80% and a significance level of 5%, 175 patients are included (including a drop-out rate of 15%). Secondary objective criteria are progression-free survival, overall survival, acute and late toxicity, and quality of life.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically confirmed adenoid cystic carcinoma in the head and neck area
non-operable or
R1/R2 resected or
perineural sheat invasion (Pn+) or
Disqualifiers
rejection of the study by the patient
Patient is not able to consent
Stage IV (distant metastases), except lung metastases < 1cm
lymph node involvement (clinical or pathological)
Trial design
Parallel
Treatments tested in this trial
Carbon ion irradiation
Radiation22 x 3 Gy(RBE) Carbon Ions
Bimodal irradiation
Radiation25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
Treatment groups
Trial outcomes
Primary outcomes
Freedom from loco-regional progression
Freedom from loco-regional tumor progression according to MR imaging
Secondary outcomes
Progression-free survival
Progression-free survival
Overall survival
Overall survival
Acute toxicities
Acute toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity \> 2 grade)
Late toxicities
Late toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity \> 2 grade)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.